Forget Ozempic and Mounjaro, this firm is on the edge of a weight-loss breakthrough
This year, drug companies have been living under a cloud of uncertainty created by the Trump administration. Threats of tough action on drug pricing and tariffs have fuelled nervousness, while recently agreed cuts to Medicaid in the 'big beautiful bill' are also causing concern.
But medicine will always be a priority for the sick, and innovations from the pharmaceutical industry are vital for creating healthier societies as populations age.
Biotech giant Amgen looks particularly well placed to weather current uncertainties and prosper from the long-term prospects of its industry.
A first-class dividend record, which includes increased payouts in each of the last 13 years, is testament to the resilience of the business. Key to this is that unlike many rivals, no one product dominates Amgen's $33.4bn (£24.7bn) of sales.
In fact, the company boasts 14 blockbuster drugs with over $1bn sales each.
This product diversity means that while its biggest selling treatment – an osteoporosis drug called Prolia that generated $4.4bn revenues last year – is expected to see rapid declines following its loss of patent protection in February, the company's top line is forecast to grow.
The drugs Amgen sells cover a number of different areas, including cancer, cardiovascular disease, osteoporosis and rare diseases. Recent trading has been strong, too, with 21 drugs reporting record sales last year and 14 reporting double-digit growth.
Amgen is experiencing particularly strong growth from cholesterol drug Repatha, which is forecast to net $2.8bn this year, and osteoporosis treatment Evenity, both of which target underserved patient groups. Sales are also soaring for cancer drug Blincyto.
In terms of the problems posed by Trump, Amgen looks well placed. Tariffs should not be a major issue given it mostly manufactures in the US, where it is currently increasing capacity. Having just opened a new facility in Ohio, it plans to plough another $900m into growth in the state and a further $1bn is being spent building in North Carolina.
Much of this spending is aimed at increasing production of biosimilars, which are lower cost versions of existing drugs that have lost patent protection. This focus should help position the group to deal with the US government's drug-pricing agenda because biosimilars help lower healthcare costs.
Amgen has said Medicaid cuts could have a material adverse impact on some drug sales, however, the cuts passed in the big beautiful bill last week were scaled back in order to get it approved.
Reassurance about prospects can also be taken from the number of top fund managers backing the stock – all among the best-performing 3pc globally according to financial publisher Citywire.
A total of 14 of these individuals back the shares. The level of smart-money backing has won Amgen a place in Citywire's Global Elite Companies index, which is home to the 76 very best ideas from among the c.6,000 stocks held across the portfolios of the top managers Citywire tracks.
For these backers, the potential of Amgen's drug development is a key part of its attraction.
Investors have been particularly excited about a long-lasting obesity drug Amgen has begun late-stage phase III trials for, called MariTide.
It produces similar levels of weight-loss as Wegovy and Zepbound, which are multibillion-dollar treatments made by Novo Nordisk and Eli Lilly respectively, but MariTide only needs to be injected once a month or less, compared with weekly for the existing drugs.
While the potential is exciting, the market reacted negatively to recent news of high levels of nausea during early use. Amgen reckons it can address this by starting patients on lower doses.
Better trial news has recently come from cancer treatments, specifically a stomach cancer drug called Bemarituzumab. Amgen is also looking to extend the uses of some of its existing blockbuster medicines.
The company put a record $6bn into research and development last year pursuing new opportunities, which represented more than 18pc of sales and a 25pc increase on 2023.
While Amgen's margins have nudged down over recent years, it is nevertheless highly profitable. It reported 46.9pc underlying operating margins last year. Meanwhile, solid earnings per share growth is predicted over the next two years of just over 4pc on an annualised basis.
That looks an attractive package with the shares priced at 14 times forecast earnings and yielding 3.4pc, especially once the potential for positive surprises from the busy development pipeline is factored in.
British buyers of the shares need to fill out the correct paperwork to minimise withholding taxes and check for any extra dealing costs with brokers.
Questor says: buy
Ticker: NYSE:AMGN
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
29 minutes ago
- Reuters
SoftBank and OpenAI's Stargate aims building small data center by year-end, WSJ reports
July 21 (Reuters) - Stargate, a multi-billion-dollar effort by ChatGPT's creator OpenAI, SoftBank (9434.T), opens new tab and Oracle (ORCL.N), opens new tab to supercharge the U.S.' AI ambitions is now setting the more modest goal of building a small data center by the end of the year, likely in Ohio, the Wall Street Journal reported on Monday. In January, U.S. President Donald Trump hosted top tech CEOs at the White House to highlight the $500 billion Stargate Project, which would create more than 100,000 jobs in the country. SoftBank and OpenAI, which jointly lead the joint venture, have been at odds over crucial terms of the partnership, including where to build the sites, the report said, citing people familiar with the matter. In a joint statement, the two companies told Reuters they were moving "with urgency on site assessments" and were also advancing projects in multiple states. When the project was unveiled, the companies involved, along with other equity backers of Stargate, had committed $100 billion for immediate deployment, with the remaining investment expected to occur over the next four years. Oracle Chairman Larry Ellison said at the time that the first of the project's data centers was already under construction in Texas. Trump has prioritized winning the AI race against China and declared, on his first day in office, a national energy emergency aimed at removing all regulatory obstacles to oil and gas drilling, coal and critical mineral mining, and building new gas and nuclear power plants to bring more energy capacity online.
Reuters
29 minutes ago
- Reuters
Humana renews challenge to downgrade of US Medicare 'star' ratings
July 21 (Reuters) - Humana (HUM.N), opens new tab on Monday filed a new lawsuit over the U.S. government's reduction in the health insurer's star ratings for government-backed Medicare plans, after an earlier challenge was dismissed on technical grounds. Humana, in the lawsuit in Fort Worth, Texas, federal court, says the lower ratings could cause it to lose customers and potentially billions of dollars in bonus payments from the government, which would have been used to reduce premiums and increase benefits for its members. U.S. District Judge Reed O'Connor in Fort Worth dismissed those claims last week, finding Humana had failed to exhaust all of its out-of-court options to challenge the ratings. In the new lawsuit, Humana says it has in recent months exhausted an administrative appeals process, giving the insurer standing to sue. "A final Star Rating determines legal rights and obligations, and legal consequences flow from them," the company said. The U.S. Department of Health and Human Services, which oversees Medicare, did not immediately respond to a request for comment. Humana is one of the largest providers of Medicare Advantage plans in the U.S., which are funded by the Medicare health insurance program for seniors and some disabled people but administered by private insurers. The U.S. Centers for Medicare and Medicaid Services, which is part of HHS, issues star ratings for the plans, from one to five stars, to help beneficiaries choose. Plans with higher star ratings receive higher payments from the government if they keep costs below certain targets. Those bonus payments can be worth hundreds of millions or billions of dollars. Humana first sued HHS in October, after CMS finalized the 2025 star ratings. Like the complaint that was dismissed by O'Connor, Monday's lawsuit challenges the way the ratings were calculated and seeks an order directing CMS to set aside Humana's 2025 ratings and recalculate them.
Reuters
29 minutes ago
- Reuters
US Treasury's Bessent calls for review of Fed non-monetary policy operations
WASHINGTON, July 21 (Reuters) - U.S. Treasury Secretary Scott Bessent said the Federal Reserve's vital independence on monetary policy is threatened by its "mandate creep" into non-policy areas and he called on the U.S. central bank to conduct an exhaustive review of those operations. The Fed's autonomy "is threatened by persistent mandate creep into areas beyond its core mission, provoking justifiable criticism that unnecessarily casts a cloud over the Fed's valuable independence on monetary policy," Bessent said in a post on X. He called Fed monetary policy "a jewel box" that should be walled off to preserve its independence, which he called a cornerstone of continued U.S. economic growth and stability. Bessent said a review should be conducted into the Fed's decision to launch a massive renovation project of its headquarters at a time when it is posting operating losses. He did not say who should conduct that review, adding that he has "no knowledge or opinion on the legal basis" for the project. President Donald Trump has railed repeatedly against Fed Chair Jerome Powell and urged him to resign because of the central bank's reluctance to cut interest rates. In recent days Trump has also taken aim at the $2.5 billion renovation at the Fed's almost 100-year-old Washington headquarters, which has exceeded its budget, suggesting there could be fraud involved and that might be a reason to oust Powell. A recent Supreme Court opinion has solidified a long-standing interpretation of the law that the Fed chair cannot be fired over policy differences but only "for cause." The Fed's Board of Governors approved the renovation project, opens new tab in 2017, during Trump's first term, and received design approval from the National Capital Planning Commission in 2020 and 2021. Speaking with CNBC earlier on Monday, Bessent declined to comment on a report that he had advised Trump not to fire Powell, saying it would be the president's decision. "If this were the (Federal Aviation Administration) and we were having this many mistakes, we would go back and look at why. Why has this happened?" said Bessent, whom Trump has mentioned as a possible candidate to replace Powell. "All these PhDs over there, I don't know what they do." Powell last week responded to a Trump administration official's demands for information about cost overruns on the renovation project, saying it was large in scope and involved a number of safety upgrades and hazardous materials removals. Bessent declined to be drawn on predictions that U.S. financial markets could crash if Powell was ousted. Powell's term as chair ends in May 2026, although he is due to stay on as a Fed governor through January 2028. Bessent noted another governor seat will come open in January.
